Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia Therapeutics Announces First Quarter 2020 Financial Results
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates